Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1600 1625 1641 1645 1674 1677 1678 1758
This examiner grants 34% of resolved cases
Ellen Jean Marcsisin has resolved 365 cases in Art Unit 1600 of Tech Center 1700. Her allowance rate is 34.5 percent. This percentage is a primary metric for practitioners to consider when evaluating the examiner's history. The data also shows an interview lift of 49.3 percent. This 49.3 percent lift indicates the change in allowance probability associated with an interview.
The median days to allowance is 3561. This 3561-day figure represents the duration of the prosecution process for cases that reach a grant. Practitioners should consider the 365 resolved cases as a historical record of the examiner's work. The 34.5 percent allowance rate and 49.3 percent interview lift are components of the examination profile. The median pendency is a factor for managing client expectations.
Direct communication is a documented tactic, as shown by the lift. Applicants should review the allowance rate as they prepare their prosecution strategy. The cases provide a data set for understanding the examiner's approach in Tech Center 1700. The timeline is a measure of the time required to navigate Art Unit 1600 to a successful conclusion.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18617851 | IMMUNOCHROMATOGRAPHY KIT AND ASSAY APPARATUS | Non-Final OA | FUJIFILM Corporation |
| 18044371 | SYSTEMS AND METHODS FOR THE AMPLIFIED DETECTION OF MOLECULES ON MICROPARTICLES | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18004402 | SINGLE-MOLECULE, REAL-TIME, LABEL-FREE DYNAMIC BIOSENSING WITH NANOSCALE MAGNETIC FIELD SENSORS | Final Rejection | Western Digital Technologies, Inc. |
| 18604573 | METHODS FOR OBTAINING ANTIBODY MOLECULES WITH HIGH AFFINITY | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 16880736 | METHODS FOR IDENTIFYING AND QUANTITATING HOST CELL PROTEIN | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18300689 | ELECTROCHEMILUMINESCENCE METHOD OF DETECTING AN ANALYTE IN A LIQUID SAMPLE AND ANALYSIS SYSTEM | Non-Final OA | Hitachi High-Tech Corporation |
| 18334135 | TRANS-INTERFACIAL MAGNETIC SEPARATION | Non-Final OA | Northwestern University |
| 17891458 | IDENTIFICATION OF PATIENTS WITH ABNORMAL FRACTIONAL SHORTENING | Final Rejection | Roche Diagnostics Operations, Inc. |
| 17162140 | Use of Biomarkers in the Assessment of the Early Transition from Arterial Hypertension to Heart Failure | Final Rejection | Roche Diagnostics Operations, Inc. |
| 16625282 | QUANTIFICATION, ISOLATION, AND CHARACTERIZATION OF EXOSOMES USING DROPLET-BASED AND WELL-BASED MICROFLUIDIC SYSTEMS | Final Rejection | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY |
| 18424571 | METHOD FOR THE DETECTION OF ORGAN DERIVED EXTRACELLULAR VESICLES | Non-Final OA | Hoffmann-La Roche Inc. |
| 18472987 | COMPOSITION FOR PREVENTING OR TREATING OF ISCHEMIC CEREBROVASCULAR DISEASE COMPRISING AN ARGINASE-1 INHIBITOR | Non-Final OA | Ajou University Industry-Academic Cooperation Foundation |
| 18145873 | SYSTEMS AND METHODS FOR DETECTION OF LAMININ BETA-1 SUBUNIT WITHIN TISSUE | Non-Final OA | Axogen Corporation |
| 17821835 | Method of Antigen-Binding Protein Production | Non-Final OA | AMGEN INC. |
| 18841308 | ANTI-PEG ANTIBODY BINDING MATERIAL AND METHOD FOR DETECTING ANTI-PEG ANTIBODY | Non-Final OA | DKS Co. Ltd. |
| 14663560 | BIOASSAY SYSTEM AND METHOD FOR DETECTING ANALYTES IN BODY FLUIDS | Final Rejection | INSTRUMENTATION LABORATORY COMPANY |
| 17051278 | METHODS AND COMPOSITIONS FOR POINT OF CARE MEASUREMENT OF THE BIOAVAILABILITY OF THERAPEUTIC BIOLOGICS | Final Rejection | GENALYTE, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy